165528-69-8

Basic information

• Product Name: 4-(T-BOC-AMINOMETHYL)-3-CHLOROBENZOIC ACID
• Synonyms: 4-(T-BOC-AMINOMETHYL)-3-CHLOROBENZOIC ACID;3-Chloro-4-[(Boc-amino)methyl]benzoic acid
• CAS NO: 165528-69-8
• Molecular Formula: C₁₃H₁₆ClNO₄
• Molecular Weight: 285.72
• Mol File: 165528-69-8.mol

Chemical Properties

• Boiling Point: 448.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.269±0.06 g/cm3(Predicted)
• PKA: 3.88±0.10(Predicted)
• CAS DataBase Reference: 4-(T-BOC-AMINOMETHYL)-3-CHLOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(T-BOC-AMINOMETHYL)-3-CHLOROBENZOIC ACID(165528-69-8)
• EPA Substance Registry System: 4-(T-BOC-AMINOMETHYL)-3-CHLOROBENZOIC ACID(165528-69-8)

Safety Data

• Hazardous Substances Data: 165528-69-8(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 74733-30-5 methyl 4-Bromomethyl-3-chlorobenzoate 
• 56525-63-4 methyl 3-chloro-4-methyl-benzoate 
• 940062-11-3 4-aminomethyl-3-chlorobenzoic acid methyl ester 

Downstream Products

• 384832-06-8 1-(4-[tert-Butyloxycarbonylaminomethyl]-3-chlorobenzoyl)-5-methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 479234-81-6 (2S,4R)-1-[2-Chloro-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-benzylcarbamoyl]-4-methoxy-pyrrolidine-2-carboxylic acid 
• 479234-76-9 (2S,4R)-1-[2-Chloro-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-benzylcarbamoyl]-4-methoxy-pyrrolidine-2-carboxylic acid methyl ester 
• 479234-92-9 (4-aminomethyl-3-chloro-phenyl)-(5,6,7,8-tetrahydro-thieno[3,2-b]azepin-4-yl)-methanone 
• 785040-42-8 [2-chloro-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-benzyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS

The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.

Non-peptide oxytocin agonists

The first non-peptide, low molecular weight agonists of the hormone oxytocin (OT) are reported. The most potent compound, 39, showed an EC 50 = 33 nM and was selective for the OT receptor. A library of compounds targeted to the vasopressin/oxytocin family of receptors was screened for activity at a cloned human oxytocin receptor using a reporter gene assay. Potency and selectivity were optimised to afford compound 39, EC50 = 33 nM. This series of compounds represents the first disclosed, non-peptide, low molecular weight agonists of the hormone oxytocin (OT).

Fused azepine derivatives and their use as antidiuretic agents

Compounds according to general formulae (1 and 2), wherein G1 is an azepine derivative and G2 is a group according to general formulae (9-11) are new. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

Bicyclic vasopressin agonists

Compounds according to general formula (1), and pharmaceutically acceptable salts thereof, wherein V is a covalent bond or NH, X is selected from CH2, O and N-alkyl, Z is either S or —CH═CH—, R1and R2are independently sele

Condensed azepines as vasopressin agonists

This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, O

Bicyclic fibrinogen antagonists

This invention relates to compounds of the formulae: wherein A1is O, S, N—R1or CHR1; A4is N—R4or CHR4; R2is a sidechain containing an acid or ester group; R1, R4and R5are substituents such as H, alkyl and aryl alkyl, and R6is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.